AGEN · Agenus Inc.

Agenus Inc. reported transformative Q1 2026 results, swinging from operating and net losses to profitability. Revenue grew 40.2% year-over-year to $33.7 million from $24.1 million, matched by gross profit of $33.7 million (41.0% increase from $23.9 million), yielding a 100% gross margin. This topline expansion underpinned operating income of $15.1 million (44.6% operating margin), a stark reversal from the prior-year $13.3 million operating loss (213.1% improvement). Net income reached $39.2 million from a $26.4 million loss (248.7% change), with diluted EPS at $1.02 versus -$1.03 (199.0% improvement).

These gains reflect disciplined execution in a transitioning business model. Cost management measures preserved liquidity while advancing core priorities, enabling the profitability inflection. The 100% gross margin signals a high-margin revenue profile, likely bolstered by non-cash royalty components and strategic shifts away from lower-margin activities.

Cash dynamics showed operating cash use of -$35.95 million, worsening from -$25.62 million prior year, with free cash flow at -$36.0 million as capital expenditures were negligible ($0). This burn stems from payments substantially settling liabilities accrued in prior periods, captured in the period-over-period accounts payable decrease rather than current operating expenses. Such normalization post-restructuring supports sustainable operations without distorting profitability metrics.

Management's focus channels capital to BOT/BAL in colorectal cancer and select tumors, the clearest path to clinical and commercial value. While Q1 profitability marks progress, advancing registration, commercialization, and profitability will require additional capital. Plans include third-party provider agreements, anticipating significant expenditures to execute programs. Cost measures and liquidity preservation position Agenus to navigate this path, leveraging equity investments with readily determinable fair values from exchange pricing.